Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.

Human molecular genetics - 15 Dec 2013

Morales Maria Gabriela, Gutierrez Jaime, Cabello-Verrugio Claudio, Cabrera Daniel, Lipson Kenneth E, Goldschmeding Roel, Brandan Enrique

Abstract excerpt

In Duchenne muscular dystrophy (DMD) and the mdx mouse model, the absence of the cytoskeletal protein dystrophin causes defective anchoring of myofibres to the basal lamina. The resultant myofibre degeneration and necrosis lead to a progressive loss of muscle mass, increased fibrosis and ultimate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to p38 Mitogen-Activated Protein Kinases
Share to Cell- and Tissue-Based Therapy
Share to Connective Tissue Growth Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred mdx

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Muscle Strength

Share to Smad Proteins

Source

Identifiers

PMID: 23904456
DOI: 10.1093/hmg/ddt352

Genes

DMD
CCN2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23904456-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.PMID 23904456Read ↗

Genetic manipulation of CCN2/CTGF unveils cell‐specific ECM‐remodeling effects in injured skeletal muscleSemantic proximity Read ↗

Lack of miR-378 attenuates muscular dystrophy in mdx miceSemantic proximity Read ↗

Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular DystrophySemantic proximity Read ↗

Targeting Fibrosis in Duchenne Muscular DystrophySemantic proximity Read ↗

Distinct extracellular matrix states uncouple collagen accumulation from pathological fibrosis in Duchenne muscular dystrophySemantic proximity Read ↗

Humanization of the mdx Mouse Phenotype for Duchenne Muscular Dystrophy Modeling: A Metabolic Perspective.Semantic proximity Read ↗

Current Translational Research and Murine Models For Duchenne Muscular DystrophySemantic proximity Read ↗

Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosisSemantic proximity Read ↗

Disease exacerbation by fibroblast inclusion in Duchenne Muscular Dystrophy MYOrganoids reveals limitations of microdystrophin therapeutic efficacySemantic proximity Read ↗

Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy.Semantic proximity Read ↗

A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx miceSemantic proximity Read ↗

GDF5 modulation of MuSC pool as a potential therapeutic benefit for DMDSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.